Novo Nordisk Weighs Strong Pipeline Data Against Steep Revenue Warning as Shares Languish
Novo Nordisk stock plunges 41% in a year despite strong uptake of oral Wegovy and positive CagriSema trial…
Generics, Price Wars, and a Steep Valuation Gap
Novo Nordisk faces a turbulent period with a 20% stock drop, Eli Lilly’s US market dominance, and Canada’s…
Novo Nordisk’s Buyback Blitz and FDA Fast-Track Mask a Steep Profit Slide
Novo Nordisk spends billions on share repurchases but faces a 50% stock drop, 2026 revenue decline, and fierce…
Novo Nordisk Bets on AI and Subscriptions to Counter a Steep Slide
Novo Nordisk shares surge as the firm partners with OpenAI to accelerate drug development and expands Wegovy subscription…
Novo Nordisk’s Clinical Edge and US Push Battle a Steep Share Decline
Novo Nordisk posts strong clinical data and expands Wegovy, yet shares are down 22% YTD. Can its May…
Novo Nordisk’s Clinical Edge and US Push Battle a Steep Share Decline
Novo Nordisk posts strong clinical data and expands Wegovy, yet shares are down 22% YTD. Can its May…
Novo Nordisk Bets on AI and New Products to Reverse Steep Share Slide
Novo Nordisk shares rebound on UK Wegovy pen approval. The firm combats a weak outlook with an OpenAI…